NIH Deepens Investment In Avonex and Copaxone Combination Study

Article Date: 22 Jul 2009 – 4:00 PDT The first large-scale “CombiRX” clinical trial testing the combined use of FDA-approved interferon beta-1a (Avonex®) and glatiramer acetate (Copaxone®) [...]

• Caroline says: This is the largest MS trial ever supported by NIH. Cumulative investment is $44 million. Nice work, NIH. In the trial, combination therapy (Avonex and Copaxone) is being compared to the use of either agent alone for 36 months. All participants are receiving at least one active medication and there is not a placebo-only treatment arm.